Thanks but no thanks: Why MSF is rejecting donated vaccines from Pfizer

MSF hopes to pressure Pfizer to join GlaxoSmithKline in lowering the price of pneumococcal conjugate vaccine for middle- and upper-income countries, where it is often unaffordable.

About the author

  • Molly Anders

    Molly Anders is a former U.K. correspondent for Devex. Based in London, she reports on development finance trends with a focus on British and European institutions. She is especially interested in evidence-based development and women’s economic empowerment, as well as innovative financing for the protection of migrants and refugees. Molly is a former Fulbright Scholar and studied Arabic in Syria, Jordan, Egypt and Morocco.